SUBJECTS : Therapeutics | Pharmacology | Antibodie
Antibody Therapeutics: 2022, vol: 5, issue: 3
- 1)- Patrick Renner, Michael Crone, Matthew Kornas, KimAnh T Pioli, Peter D Pioli. Intracellular flow cytometry staining of antibody-secreting cells using phycoerythrin-conjugated antibodies: pitfalls and solutions. Antibody therapeutics. 2022, 5 (3): 151-163
Cited : 0Read More - 2)- Mengyu Li, Sen Mei, Yi Yang, Yuelei Shen, Lei Chen. Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective. Antibody therapeutics. 2022, 5 (3): 164-176Cited : 2Read More
- 3)- Muhammad S Khan, Eun Kim, Alex McPherson, Florian J Weisel, Shaohua Huang, Thomas W Kenniston, Elena Percivalle, Irene Cassaniti, Fausto Baldanti, Marlies Meisel, Andrea Gambotto. Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein. Antibody therapeutics. 2022, 5 (3): 177-191Cited : 3Read More
- 4)- Moon-Sung Jang, Nurain Syahirah Binti Ismail, Yeon Gyu Yu. Development of a human antibody that exhibits antagonistic activity toward CC chemokine receptor 7. Antibody therapeutics. 2022, 5 (3): 192-201Cited : 0Read More
- 5)- Lei Jia, Mani Jain, Yaxiong Sun. Improving antibody thermostability based on statistical analysis of sequence and structural consensus data. Antibody therapeutics. 2022, 5 (3): 202-210Cited : 0Read More
- 6)- Joshua R Laber, Thomas M Laue, Dana I Filoti. Use of Debye-Hückel-Henry charge measurements in early antibody development elucidates effects of non-specific association. Antibody therapeutics. 2022, 5 (3): 211-215Cited : 1Read More
- 7)- Bo Wang, Jun Lin, Matthew R Hoag, Meredith Wright, Mingjun Ma, Wenyan Cai, Sachith Gallolu Kankanamalage, Yue Liu. A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies. Antibody therapeutics. 2022, 5 (3): 216-225Cited : 0Read More
- 8)- Kristopher A Lofgren, Nicolette C Reker, Sreeja Sreekumar, Paraic A Kenny. Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate. Antibody therapeutics. 2022, 5 (3): 226-231Cited : 0Read More
